8-K: DSS Inc. Amends Loan Agreement with Impact BioMedical, Extending Maturity and Increasing Principal

DSS, Inc. has amended its loan agreement with Impact BioMedical, extending the maturity date to September 30, 2030, and increasing the principal balance to $12,859,328.60.

Summary

• DSS, Inc. and Impact BioMedical, Inc. have amended a revolving promissory note originally dated March 1, 2023.
• The amendment extends the loan's maturity date to September 30, 2030.
• The principal balance of the loan has been increased to $12,859,328.60, which includes previously advanced principal and accrued interest.
• The amendment eliminates any further advance options under the original note.
• Specific repayment terms have been established, including monthly interest payments until January 31, 2026, followed by fixed monthly payments of $126,380.80 until August 31, 2030, and a final payment on September 30, 2030.
• The interest rate has been amended to a floating rate of WSJ Prime + 0.50%, initially set at 9%, with a post-maturity rate of the lesser of the maximum rate allowed by law or 18% per annum.
• The loan is secured by a blanket first lien on all of Impact's assets.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the loan terms are more favorable to DSS, the extension provides Impact with more time to repay the debt. The amendment is a standard business transaction.

Positives

• The loan maturity extension provides Impact BioMedical with more time to repay the debt.
• The establishment of a repayment schedule provides clarity and predictability for both parties.
• The loan is secured by a first lien on all of Impact's assets, providing DSS with a strong position in case of default.
• Impact has the option to prepay the loan without penalty.

Negatives

• The increased loan principal of $12,859,328.60 represents a larger debt burden for Impact BioMedical.
• The floating interest rate exposes Impact to potential increases in borrowing costs if the WSJ Prime Rate rises.
• The post-maturity interest rate of up to 18% is high and could be a significant burden if the loan is not repaid by the maturity date.

Risks

• Impact BioMedical may face challenges in meeting the repayment schedule, especially if their financial performance does not improve.
• Increases in the WSJ Prime Rate could lead to higher interest payments for Impact.
• A default by Impact could result in DSS needing to enforce its security interest, which may not fully recover the outstanding loan amount.
• The high post-maturity interest rate could significantly increase the debt burden if the loan is not repaid on time.

Future Outlook

The amended agreement provides a structured repayment plan for Impact BioMedical until September 30, 2030. The success of the loan repayment depends on Impact's ability to generate sufficient cash flow.

Industry Context

This type of loan amendment is common in situations where a borrower needs more time to repay debt or requires additional funding. It reflects a continued financial relationship between DSS and Impact BioMedical.

Comparison to Industry Standards

• The interest rate of WSJ Prime + 0.50% is within the typical range for secured loans of this nature, although the specific rate will fluctuate with the WSJ Prime Rate.
• The maturity extension to 2030 is a significant extension, which is not uncommon for companies seeking to restructure their debt.
• The use of a blanket first lien on all assets is a standard practice for secured lending, providing the lender with a strong claim on the borrower's assets in case of default.
• The repayment terms, including monthly interest payments followed by fixed principal and interest payments, are a common structure for amortizing loans.

Stakeholder Impact

• Shareholders of DSS, Inc. may view the loan amendment as a positive step, as it secures a larger loan amount with a first lien on Impact's assets.
• Impact BioMedical's stakeholders may view the loan amendment as a positive development, as it provides more time to repay the debt and continue operations.
• Creditors of Impact BioMedical may be impacted by the first lien granted to DSS, which could affect their priority in case of default.

Next Steps

• Impact BioMedical will begin making monthly interest payments on February 1, 2024.
• Impact BioMedical will make fixed monthly payments of $126,380.80 from February 1, 2026, to August 31, 2030.
• Impact BioMedical will make a final payment of all outstanding principal and interest on September 30, 2030.

Key Dates

Keywords

promissory note, loan agreement, debt financing, maturity extension, interest rate, repayment terms, secured loan, Impact BioMedical, DSS Inc.